Willis, Michael
Nilsson, Andreas
Kellerborg, Klas
Ball, Philip
Roe, Rupert
Traina, Shana
Beale, Rebecca
Newell, Isabelle
Clinical trials referenced in this document:
Documents that mention this clinical trial
New drugs in preclinical and early stage clinical development in the treatment of heart failure
https://doi.org/10.1080/13543784.2019.1551357
Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease
https://doi.org/10.1161/circulationaha.120.048740
Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria (Results)
https://doi.org/10.2215/cjn.15260920
Transforming the Care of Patients with Diabetic Kidney Disease
https://doi.org/10.2215/cjn.18641120
Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial
https://doi.org/10.2215/cjn.08980621
Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model
https://doi.org/10.1007/s13300-020-00968-x
Sodium–Glucose Cotransporter 2 Inhibitor Protection Against Adverse Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes
https://doi.org/10.2337/cd18-0064
Linear Projection of Estimated Glomerular Filtration Rate Decline with Canagliflozin and Implications for Dialysis Utilization and Cost in Diabetic Nephropathy
https://doi.org/10.1007/s13300-020-00953-4
Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease
https://doi.org/10.1161/strokeaha.120.031623
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2
https://doi.org/10.2215/cjn.10140620
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial
https://doi.org/10.1681/asn.2019111168
Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease
https://doi.org/10.2337/dbi18-0007
An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors
https://doi.org/10.1080/14740338.2019.1626823
Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial
https://doi.org/10.1681/asn.2020050723
Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes
https://doi.org/10.2337/cd16-0063
Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: an analysis from the CREDENCE trial
https://doi.org/10.1186/s12933-023-01916-2
Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial
https://doi.org/10.1161/circulationaha.123.065251
Renal and Cardiovascular Effects of sodium–glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial
https://doi.org/10.1136/bmjopen-2017-018097
Article History
Received: 8 October 2020
Accepted: 6 November 2020
First Online: 2 December 2020